在等待监管机构批准的情况下,Onco-Innovations在加拿大四个省份提交了招股说明书,以潜在地为瘤学研究筹集资金. Onco-Innovations files prospectus in four Canadian provinces to potentially raise capital for oncology research, pending regulatory approval.

Onco-Innovations Limited 已于2026年2月3日在加拿大四个省份提交了初步基础货架招股说明书，计划在25个月内可能提供普通股、债务和认股权证等证券。 Onco-Innovations Limited has filed a preliminary base shelf prospectus in four Canadian provinces, dated February 3, 2026, to potentially offer securities like common shares, debt, and warrants over 25 months. 这一行动旨在提供财务灵活性,但除非监管机构发出最后批准和补充文件,否则不会发生销售。 The move aims to provide financial flexibility, but no sales will occur until regulators issue final approval and supplements are filed. 该公司侧重于肿瘤学和固态肿瘤治疗,指出对具体产品没有作出承诺,美国证券法不适用。 The company, focused on oncology and solid tumor treatments, notes no commitments exist for specific offerings, and U.S. securities laws do not apply. 前瞻性报表存在风险,实际结果可能不同。 Forward-looking statements carry risks, and actual results may differ. SEDAR+上有更详细的资料。 More details are available on SEDAR+.